HROW
$35.23
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Recent News
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions
Harrow Inc (HROW) reports a robust 33% revenue growth in Q4 2025, with strategic plans to expand market share and product offerings in 2026.
A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns
Why Harrow stock is back in focus after its latest results Harrow (HROW) has been in the spotlight after Q4 2025 results combined strong revenue growth with an earnings miss, a back end loaded 2026 outlook, and planned spending on a larger sales force. See our latest analysis for Harrow. Harrow's latest earnings miss and back end loaded 2026 guidance have hit sentiment in the short term, with a 7 day share price return of 33.01% decline and year to date share price return of 27.53% decline,...
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Why Harrow, An IBD 50 Stock Up 32% Since January, Just Crashed
Top-notch biotech stock Harrow crumbled Tuesday after its most-watched product, an eye drop called Vevye, missed fourth-quarter expectations.